{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:31:38Z","timestamp":1791297098471,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.vph.2015.07.008","type":"journal-article","created":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T21:39:52Z","timestamp":1436996392000},"page":"10-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Glycoprotein IIb\/IIIa inhibitors: The resurgence of tirofiban"],"prefix":"10.1016","volume":"78","author":[{"given":"Shawn","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marintha","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Harmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5-6","key":"10.1016\/j.vph.2015.07.008_bb0005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000073569","article-title":"Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents","volume":"32","author":"Seligsohn","year":"2002","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"10.1016\/j.vph.2015.07.008_bb0010","series-title":"Braunwald's Heart Disease: a Textbook of Cardiovascular Medicine","year":"2012"},{"issue":"Database issue","key":"10.1016\/j.vph.2015.07.008_bb0015","doi-asserted-by":"crossref","first-page":"D901","DOI":"10.1093\/nar\/gkm958","article-title":"DrugBank: a knowledgebase for drugs, drug actions and drug targets","volume":"36","author":"Wishart","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vph.2015.07.008_bb0020","series-title":"Integrilin [package insert]","year":"2014"},{"key":"10.1016\/j.vph.2015.07.008_bb0025","series-title":"Aggrastat [package insert]","year":"2015"},{"issue":"7","key":"10.1016\/j.vph.2015.07.008_bb0030","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","volume":"60","author":"Jneid","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"25","key":"10.1016\/j.vph.2015.07.008_bb0035","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.vph.2015.07.008_bb0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.vph.2015.07.008_bb0045","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9122","key":"10.1016\/j.vph.2015.07.008_bb0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)85010-1","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.vph.2015.07.008_bb0055","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.vph.2015.07.008_bb0060","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2009.10.093","article-title":"Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)","volume":"56","author":"Akerblom","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"18","key":"10.1016\/j.vph.2015.07.008_bb0065","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jacc.2009.01.053","article-title":"Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis","volume":"53","author":"De Luca","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.vph.2015.07.008_bb0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2007.09.053","article-title":"The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention","volume":"51","author":"Gurm","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.vph.2015.07.008_bb0075","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2009.08.093","article-title":"Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial","volume":"56","author":"Zeymer","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"37","key":"10.1016\/j.vph.2015.07.008_bb0080","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur. Heart J."},{"issue":"17","key":"10.1016\/j.vph.2015.07.008_bb0085","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.97.17.1680","article-title":"Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb\/IIIa receptor blockade","volume":"97","author":"Mascelli","year":"1998","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.vph.2015.07.008_bb0090","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.amjcard.2005.07.056","article-title":"Administration of intracoronary eptifibatide during ST-elevation myocardial infarction","volume":"96","author":"Pinto","year":"2005","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.vph.2015.07.008_bb0095","first-page":"132","article-title":"Comparison between intracoronary abciximab and intravenous eptifibatide administration during primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction","volume":"8","author":"Namazi","year":"2013","journal-title":"J. Tehran Heart Cent."},{"issue":"37","key":"10.1016\/j.vph.2015.07.008_bb0100","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.vph.2015.07.008_bb0105","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1538-7836.2006.01829.x","article-title":"Thrombocytopenia associated with the use of GPIIb\/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb\/IIIa inhibitors","volume":"4","author":"Aster","year":"2006","journal-title":"J. Thromb. Haemost."},{"issue":"18","key":"10.1016\/j.vph.2015.07.008_bb0110","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1161\/01.CIR.0000127867.41621.85","article-title":"Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting","volume":"109","author":"Merlini","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.vph.2015.07.008_bb0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1018779116791","article-title":"A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb\/IIIa receptor inhibitors","volume":"9","author":"Llevadot","year":"2000","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"10.1016\/j.vph.2015.07.008_bb0120","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1537-2995.2011.03282.x","article-title":"How do I transfuse platelets (PLTs) to reverse anti-PLT drug effect?","volume":"52","author":"Sarode","year":"2012","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.vph.2015.07.008_bb0125","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1161\/01.CIR.95.4.809","article-title":"Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy","volume":"95","author":"Berkowitz","year":"1997","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.vph.2015.07.008_bb0130","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1182\/blood.V100.6.2071","article-title":"Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb\/IIIa","volume":"100","author":"Bougie","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.vph.2015.07.008_bb0135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ccd.1239","article-title":"Severe thrombocytopenia possibly related to readministration of eptifibatide","volume":"54","author":"Paradiso-Hardy","year":"2001","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"21","key":"10.1016\/j.vph.2015.07.008_bb0140","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.vph.2015.07.008_bb0145","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jacc.2008.09.060","article-title":"Abbreviated infusion of eptifibatide after successful coronary intervention: the BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial","volume":"53","author":"Fung","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.vph.2015.07.008_bb0150","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2012.01.006","volume":"5","author":"Valgimigli","year":"2012","journal-title":"JACC Cardiovasc. Interv."},{"issue":"9957","key":"10.1016\/j.vph.2015.07.008_bb0155","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.vph.2015.07.008_bb0160","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.vph.2015.07.008_bb0165","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11883-013-0371-3","article-title":"Pharmacology of antiplatelet agents","volume":"15","author":"Kalra","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"issue":"4","key":"10.1016\/j.vph.2015.07.008_bb0170","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/09537104.2010.518324","article-title":"Profound delayed thrombocytopenia presenting 16days after abciximab (Reopro(R)) administration","volume":"22","author":"Webb","year":"2011","journal-title":"Platelets"},{"issue":"14","key":"10.1016\/j.vph.2015.07.008_bb0175","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation","volume":"330","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.vph.2015.07.008_bb0180","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/01.CIR.0000087601.45803.86","article-title":"Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial","volume":"108","author":"Tcheng","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.07.008_bb0185","series-title":"Handbook of Patient Care in Cardiac Surgery","author":"Lemmer","year":"2010"},{"issue":"21","key":"10.1016\/j.vph.2015.07.008_bb0190","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators","volume":"338","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.vph.2015.07.008_bb0195","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy","volume":"339","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.vph.2015.07.008_bb0200","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","volume":"338","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.vph.2015.07.008_bb0205","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ccd.22876","volume":"77","author":"Moliterno","year":"2011","journal-title":"Catheter Cardiovasc. Interv."},{"issue":"15","key":"10.1016\/j.vph.2015.07.008_bb0210","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1001\/jama.299.15.joc80026","article-title":"Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial","volume":"299","author":"Valgimigli","year":"2008","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vph.2015.07.008_bb0215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2013.10.013","article-title":"Comparative effectiveness of upstream glycoprotein IIb\/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy","volume":"167","author":"Nazif","year":"2014","journal-title":"Am. Heart J."},{"issue":"6","key":"10.1016\/j.vph.2015.07.008_bb0220","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.297.6.591","article-title":"Routine upstream initiation vs deferred selective use of glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial","volume":"297","author":"Stone","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vph.2015.07.008_bb0225","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/eurheartj\/ehp376","article-title":"Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials","volume":"31","author":"Valgimigli","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2015.07.008_bb0230","article-title":"A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention","author":"Manoukian","year":"2016"},{"issue":"24","key":"10.1016\/j.vph.2015.07.008_bb0235","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.vph.2015.07.008_bb0240","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.CIR.97.24.2386","volume":"97","year":"1998","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.vph.2015.07.008_bb0245","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"9272","key":"10.1016\/j.vph.2015.07.008_bb0250","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial","volume":"357","author":"Simoons","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vph.2015.07.008_bb0255","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa031859","article-title":"A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel","volume":"350","author":"Kastrati","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.vph.2015.07.008_bb0260","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial","volume":"295","author":"Kastrati","year":"2006","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.vph.2015.07.008_bb0265","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.vph.2015.07.008_bb0270","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.amjcard.2014.01.404","article-title":"Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial)","volume":"113","author":"Kunadian","year":"2014","journal-title":"Am. J. Cardiol."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115001573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115001573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T22:38:42Z","timestamp":1599259122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189115001573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":54,"alternative-id":["S1537189115001573"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2015.07.008","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycoprotein IIb\/IIIa inhibitors: The resurgence of tirofiban","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2015.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}